Dow Jones Industrial Average
) is trading up 11 points at 12,992 as of Tuesday, Feb 28, 2012, 1:35 p.m. ET. During this time, 373.4 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 818.6 million. The NYSE advances/declines ratio sits at 1,538 issues advancing vs. 1,416 declining with 114 unchanged.
The Dow component leading the way higher looks to be
), which is sporting a 94-cent gain (+1.5%) bringing the stock to $65.40. This single gain is lifting the Dow Jones Industrial Average by 7.11 points or roughly accounting for 64.6% of the Dow's overall gain. Volume for Johnson & Johnson currently sits at 7.2 million shares traded vs. an average daily trading volume of 10.7 million shares.
Johnson & Johnson has a market cap of $177.51 billion and is part of the
industry. Shares are down 1.7% year to date as of Monday's close. The stock's dividend yield sits at 3.5%.
Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The company has a P/E ratio of 18.5, above the average drugs industry P/E ratio of 15.9 and above the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Johnson & Johnson as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Johnson & Johnson Ratings Report.